On August 18, 2026, the US Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) released a discussion paper proposing new approaches to regulating medical devices enabled by generative artificial intelligence (genAI), and requesting stakeholder feedback, which must be submitted by October 19, 2026. The paper is not guidance, but it offers insight into how the agency is thinking about the unique risks and evidentia…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.